

**POLICY:** Oncology (Injectable) – Vyloy Utilization Management Medical Policy

- Vyloy® (zolbetuximab-clzb intravenous infusion – Astellas)

**EFFECTIVE DATE:** 2/1/2025

**LAST REVISION DATE:** 10/30/2024

**COVERAGE CRITERIA FOR:** All Aspirus Plans

---

### **OVERVIEW**

Vyloy, a claudin 18.2-directed cytolytic antibody, is indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastrointestinal junction adenocarcinoma in adults in whose tumors are claudin 18.2 positive as determined by an FDA-approved test.<sup>1</sup>

### **Dosing Information**

The recommended first dose of Vyloy is 800 mg/m<sup>2</sup> administered by intravenous (IV) infusion.<sup>1</sup> Subsequent doses are either 600 mg/m<sup>2</sup> administered by IV infusion once every 3 weeks, or 400 mg/m<sup>2</sup> administered by IV infusion once every 2 weeks. Treatment can continue until disease progression or unacceptable adverse events.

### **Guidelines**

The National Comprehensive Cancer Network has not addressed Vyloy.

### **POLICY STATEMENT**

Prior Authorization is recommended for medical benefit coverage of Vyloy. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Vyloy as well as the monitoring required for adverse events and long-term efficacy, approval requires Vyloy to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**Automation:** None.

### **RECOMMENDED AUTHORIZATION CRITERIA**

---

Coverage of Vyloy is recommended in those who meet the following criteria:

### FDA-Approved Indication

---

**1. Gastric or Gastroesophageal Junction Adenocarcinoma.** Approve for 1 year if the patient meets ALL of the following (A, B, C, D, E, F, and G):

- A)** Patient is  $\geq 18$  years of age; AND
- B)** Patient has locally advanced unresectable or metastatic disease; AND
- C)** Tumor is claudin 18.2 positive as determined by an approved test; AND  
Note: Claudin 18.2 positivity is defined as  $\geq 75\%$  of tumor cells demonstrating moderate to strong membranous claudin 18.2 immunohistochemical staining.
- D)** Tumor is human epidermal growth factor receptor 2 (HER2)-negative; AND
- E)** Medication is used for first-line treatment; AND
- F)** Medication is used in combination with fluoropyrimidine- and platinum-containing chemotherapy; AND  
Note: Examples of fluoropyrimidines include 5-fluorouracil and capecitabine. Examples of platinum chemotherapy agents include oxaliplatin.
- G)** Medication is prescribed by or consultation with an oncologist.

**Dosing.** Approve BOTH of the following dosing regimens (A and B):

- A)** First dose: Approve 800 mg/m<sup>2</sup> administered by intravenous infusion; AND
- B)** Subsequent doses: Approve ONE of the following dosing regimens (i or ii):
  - i.** Approve 600 mg/m<sup>2</sup> administered by intravenous infusion no more frequently than once every 3 weeks; OR
  - ii.** Approve 400 mg/m<sup>2</sup> administered by intravenous infusion no more frequently than once every 2 weeks.

---

### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Vyloy is not recommended in the following situations:

- 1.** Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

### REFERENCES

- 1. Vyloy intravenous infusion [prescribing information]. Northbrook, IL: Astellas; October 2024.

**HISTORY**

<b>Type of Revision</b>	<b>Summary of Changes</b>	<b>Review Date</b>
New Policy	--	10/30/2024
Aspirus P&T Review	Policy reviewed and approved by Aspirus P&T committee. Annual review process	12/16/2024